DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-02 22:30 |
Information regarding the total number of voting rights and total number of s…
|
English | 192.4 KB | ||
| 2024-12-02 22:30 |
Information relative au nombre total des droits de vote et d’actions composant…
|
French | 99.2 KB | ||
| 2024-11-20 15:28 |
Franchissement de seuils
|
French | 268.6 KB | ||
| 2024-11-06 22:30 |
DBV Technologies Reports Third Quarter 2024 Financial Results
|
English | 269.2 KB | ||
| 2024-10-31 09:00 |
Franchissement de seuils
|
French | 272.8 KB | ||
| 2024-10-22 22:45 |
DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut…
|
French | 239.1 KB | ||
| 2024-10-22 22:45 |
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the …
|
English | 244.2 KB | ||
| 2024-10-18 22:30 |
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
|
English | 218.2 KB | ||
| 2024-10-18 22:30 |
DBV Technologies participera au prochain congrès de l'ACAAI 2024
|
French | 229.1 KB | ||
| 2024-10-14 22:30 |
Information regarding the total number of voting rights and total number of sha…
|
English | 77.5 KB | ||
| 2024-10-14 22:30 |
Information relative au nombre total des droits de vote et d’actions composant …
|
French | 86.0 KB | ||
| 2024-09-23 22:30 |
DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3…
|
French | 204.6 KB | ||
| 2024-09-23 22:30 |
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
|
English | 156.8 KB | ||
| 2024-09-04 22:30 |
DBV Technologies participera à la 26e conférence annuelle H.C. Wainwright Globa…
|
French | 174.3 KB | ||
| 2024-09-04 22:30 |
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Inves…
|
English | 173.9 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
